- $31.90bn
- $39.00bn
- $9.47bn
Zoetis falls after cutting annual revenue forecast
Zoetis edges past Q3 revenue estimates, revises FY sales view
Morning Bid Americas: Nerves rising about frothy valuations
Brief: Zoetis Announces Retirement Of Rob Polzer At The End Of 2025 And The Appointment Of Kevin Esch As President Of Research & Development For World Leader In Animal Health Beginning In 2026
Brief: Zoetis Receives European Commission Marketing Authorization For Portela® (Relfovetmab) To Alleviate Pain Associated With Osteoarthritis In Cats
Brief: Zoetis Appoints Stephanie Tilenius To Its Board Of Directors
Brief: Zoetis Receives Conditional Approval For Dectomax-CA1 Injectable For Prevention And Treatment Of New World Screwworm Myiasis In Cattle
Zoetis up after US FDA's conditional approval for cattle treatment
Brief: HHS Says FDA Conditionally Approves Dectomax-CA1 For New World Screwworm Infestations In Cattle
Brief: Zoetis Receives Positive Opinion From CVMP For Portela®
Brief: Zoetis Inc Enters Into Revolving Credit Agreement With Banks
Brief: Zoetis Announces Pricing Of $1.85 Billion Of Senior Notes
Zoetis Inc reports results for the quarter ended June 30 - Earnings Summary
Animal healthcare firm Zoetis raises annual forecast on strong pet product demand
Brief: Zoetis Inc - Declares $0.50 Per Share Dividend For Q3 2025
U.S. RESEARCH ROUNDUP-Datadog, Masimo, Waters
Zoetis Inc reports results for the quarter ended March 31 - Earnings Summary
Zoetis raises forecast for 2025 revenue, profit on weaker US dollar
Explainer: How bird flu has sent US eggs prices skyrocketing